Funded Biotechnology Startups in Montréal
The 18 most recent funding rounds among Montréal-based biotechnology companies span from May 2021 through August 2025, covering stages from Pre-Seed to Ser…
The 18 most recent funding rounds among Montréal-based biotechnology companies span from May 2021 through August 2025, covering stages from Pre-Seed to Series C. The two largest disclosed rounds belong to Inversago Pharma ($69M Series C, October 2022) and Nomic ($42M Series B, September 2024). Early-stage momentum continues into 2025: Seed rounds closed for Synucure Therapeutics ($3M, April), Avitia ($5M, February), and Cura Therapeutics (undisclosed, May), while Cannara Biotech added $7M in August 2025.
Therapeutics-focused names — Cura, Synucure, Neurenati, and Congruence Therapeutics — account for four of the 18 entries, with three pharma-labeled companies (Inversago Pharma, Betterlife Pharma, Giiant Pharma) adding to that concentration. Three rounds carry undisclosed amounts (Cura Therapeutics, MY01, AAVAA). Non-equity instruments also appear: Sensoreal received a $230K grant in July 2022, and Hyasynth Bio closed $3M in debt financing in December 2021.
Most recent rounds
18 shownRelated listings
Frequently asked
What are the largest disclosed funding rounds in this Montréal biotech dataset?
Inversago Pharma leads with a $69M Series C closed in October 2022, followed by Nomic's $42M Series B in September 2024. Congruence Therapeutics raised $15M in a Series A in March 2023, and Theratechnologies secured $13M in October 2023, rounding out the top four by disclosed amount.
Which companies raised the most recent rounds?
The three most recent entries are Cannara Biotech ($7M, August 2025), Betterlife Pharma ($1M, May 2025), and Cura Therapeutics (undisclosed Seed, May 2025). Synucure Therapeutics also closed a $3M Seed round in April 2025.
How active is early-stage funding in this cohort?
Four Seed rounds appear in the dataset — Neurenati Therapeutics ($2M, April 2024), Avitia ($5M, February 2025), Synucure Therapeutics ($3M, April 2025), and Cura Therapeutics (undisclosed, May 2025) — plus one Pre-Seed entry: Modulari-T Biosciences at $500K in April 2023. Three of the four Seed rounds closed within roughly 14 months ending May 2025.
How many rounds in this dataset have undisclosed amounts?
Three of the 18 rounds list undisclosed amounts: Cura Therapeutics (Seed, May 2025), MY01 (Series Unknown, August 2024), and AAVAA (Series Unknown, May 2023). Among the 15 rounds with disclosed figures, amounts range from $230K (Sensoreal grant) to $69M (Inversago Pharma Series C).
What is the breakdown of round types across these 18 companies?
"Series Unknown" is the most common classification, covering seven entries: Cannara Biotech, Betterlife Pharma, NeuroTracker, MY01, Ananda Devices, Theratechnologies, and AAVAA. Seed rounds account for four entries. The dataset also includes one each of Pre-Seed, Series A, Series B, Series C, Grant, and Debt Financing, plus one entry (Giiant Pharma) with no round type listed.
Are there any non-equity funding instruments visible in this data?
Yes. Sensoreal received a $230K grant in July 2022, and Hyasynth Bio closed $3M in debt financing in December 2021. These are the only two non-equity instruments among the 18 rounds shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.